Galderma, the skincare and dermatology company, raised its 2026 sales growth outlook on Tuesday after reporting a strong second quarter. The company's net sales rose 23.8% year over year to $1.66 billion on a constant-currency basis, beating analyst expectations. European investment bank Berenberg responded by lifting its price target on the stock to CHF204, up from a previous target, and upgrading its forecasts.
What drove the strong quarter?
Galderma's pitch to investors is that its "integrated" business model—a broad product lineup spanning prescription treatments, over-the-counter skincare, and injectable aesthetics, combined with close ties to dermatologists and aesthetic practitioners—can keep demand steady even when consumers tighten their belts. The second quarter results suggest that strategy is working.
The company reported that constant-currency net sales rose 23.8% year over year to $1.66 billion. Berenberg noted that the beat flowed through to stronger first-half core EBITDA (a measure of cash profit that strips out certain non-cash items) than the market had expected. Core EBITDA is a key metric for investors because it shows how much cash the business is generating from its core operations, which can be used for reinvestment, debt repayment, or returning capital to shareholders.
Why the outlook matters
Galderma raised its 2026 sales growth outlook, signaling confidence that the momentum will continue. The company did not provide specific new numbers in the brief, but the upgrade suggests management sees sustained demand for its products, even as some consumer-facing companies have warned of a pullback in spending.
The move is part of a broader trend among companies in the healthcare and consumer sectors that are benefiting from resilient demand. For context, other firms like Hermès have also reported strong sales recently, though luxury goods and skincare serve different customer bases. Galderma's focus on medical-grade products and practitioner relationships may give it an edge in retaining customers during economic uncertainty.
What it means for investors
For everyday investors, Galderma's results highlight the potential of companies that combine healthcare credibility with consumer appeal. The company's integrated model—selling both prescription and over-the-counter products through a network of dermatologists and clinics—can create a moat against competitors. When consumers cut back on discretionary spending, they may still prioritize skincare treatments recommended by their doctor.
Berenberg's price target increase to CHF204 suggests the stock has room to run, but investors should note that price targets are just analyst opinions and not guarantees. The stock's performance will depend on whether Galderma can maintain its growth trajectory, especially as competition in the aesthetics market heats up.
Investors should also watch for any signs of a slowdown in consumer spending, which could affect Galderma's results. The company's strong Q2 came during a period when many consumers were still spending on experiences and personal care, but that could change if the economy weakens. For comparison, Electrolux recently beat profit forecasts but saw North American sales still falling, showing that consumer demand can be uneven across sectors.
Broader market context
Galderma's update comes amid a mixed earnings season for European companies. While some firms like Telefónica have lifted their cash flow targets after strong quarters, others have been more cautious. The healthcare and personal care sectors have generally held up well, as demand for medical treatments and skincare tends to be less cyclical than for big-ticket items.
The company's focus on constant-currency sales growth is important because it strips out the impact of exchange rate fluctuations, giving a clearer picture of underlying business performance. With the Swiss franc (Galderma is based in Switzerland) fluctuating against other major currencies, this metric helps investors compare results across periods.
What to watch next
Investors will be watching for Galderma's full-year results and any further updates on its 2026 outlook. The company's ability to maintain its growth rate will depend on new product launches, expansion into new markets, and the health of the aesthetics industry. Regulatory changes or shifts in consumer preferences could also affect the business.
For now, the raised outlook and analyst support suggest that Galderma is on solid footing. But as with any stock, investors should do their own research and consider how it fits into their overall portfolio, rather than chasing a price target.
